WO2022240431A1 - Champ opératoire pour l'utilisation sur une peau fragile et son procédé d'utilisation - Google Patents
Champ opératoire pour l'utilisation sur une peau fragile et son procédé d'utilisation Download PDFInfo
- Publication number
- WO2022240431A1 WO2022240431A1 PCT/US2021/046940 US2021046940W WO2022240431A1 WO 2022240431 A1 WO2022240431 A1 WO 2022240431A1 US 2021046940 W US2021046940 W US 2021046940W WO 2022240431 A1 WO2022240431 A1 WO 2022240431A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drape
- grams
- skin
- lipoglycopeptides
- itraconazole
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 9
- 239000000017 hydrogel Substances 0.000 claims abstract description 25
- 239000000853 adhesive Substances 0.000 claims abstract description 10
- 230000001070 adhesive effect Effects 0.000 claims abstract description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 15
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- 239000002002 slurry Substances 0.000 claims description 9
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 8
- 229930186147 Cephalosporin Natural products 0.000 claims description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 8
- 108010004718 Lipoglycopeptides Proteins 0.000 claims description 8
- 229940088710 antibiotic agent Drugs 0.000 claims description 8
- 229940124587 cephalosporin Drugs 0.000 claims description 8
- 150000001780 cephalosporins Chemical class 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 229960004130 itraconazole Drugs 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 229940121375 antifungal agent Drugs 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 4
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 4
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 4
- 108010064760 Anidulafungin Proteins 0.000 claims description 4
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 4
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 4
- 108010020326 Caspofungin Proteins 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 4
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 claims description 4
- 108010015899 Glycopeptides Proteins 0.000 claims description 4
- 102000002068 Glycopeptides Human genes 0.000 claims description 4
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 claims description 4
- 108010028921 Lipopeptides Proteins 0.000 claims description 4
- 108010021062 Micafungin Proteins 0.000 claims description 4
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 4
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 4
- 229920000153 Povidone-iodine Polymers 0.000 claims description 4
- 229930189077 Rifamycin Natural products 0.000 claims description 4
- 108010034396 Streptogramins Proteins 0.000 claims description 4
- 239000004098 Tetracycline Substances 0.000 claims description 4
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 4
- 229930185860 Tuberactinomycin Natural products 0.000 claims description 4
- 229940126575 aminoglycoside Drugs 0.000 claims description 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 4
- 229960003942 amphotericin b Drugs 0.000 claims description 4
- 229960003348 anidulafungin Drugs 0.000 claims description 4
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 claims description 4
- -1 antifungals Substances 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 229940121357 antivirals Drugs 0.000 claims description 4
- 229940041011 carbapenems Drugs 0.000 claims description 4
- 229960003034 caspofungin Drugs 0.000 claims description 4
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 claims description 4
- 229960005091 chloramphenicol Drugs 0.000 claims description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 4
- 229960004022 clotrimazole Drugs 0.000 claims description 4
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 4
- 239000003086 colorant Substances 0.000 claims description 4
- 229960004884 fluconazole Drugs 0.000 claims description 4
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 4
- 229960004413 flucytosine Drugs 0.000 claims description 4
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 4
- 229940124307 fluoroquinolone Drugs 0.000 claims description 4
- 229960002867 griseofulvin Drugs 0.000 claims description 4
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 229960004922 isavuconazonium Drugs 0.000 claims description 4
- RSWOJTICKMKTER-QXLBVTBOSA-N isavuconazonium Chemical compound CNCC(=O)OCC1=CC=CN=C1N(C)C(=O)OC(C)[N+]1=CN(C[C@@](O)([C@@H](C)C=2SC=C(N=2)C=2C=CC(=CC=2)C#N)C=2C(=CC=C(F)C=2)F)N=C1 RSWOJTICKMKTER-QXLBVTBOSA-N 0.000 claims description 4
- 229960004125 ketoconazole Drugs 0.000 claims description 4
- 229940041028 lincosamides Drugs 0.000 claims description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 4
- 229940041033 macrolides Drugs 0.000 claims description 4
- 238000002483 medication Methods 0.000 claims description 4
- 229960000282 metronidazole Drugs 0.000 claims description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 4
- 229960002159 micafungin Drugs 0.000 claims description 4
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 claims description 4
- 229960002509 miconazole Drugs 0.000 claims description 4
- 229940041009 monobactams Drugs 0.000 claims description 4
- 229960000564 nitrofurantoin Drugs 0.000 claims description 4
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims description 4
- 229960000988 nystatin Drugs 0.000 claims description 4
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 4
- 150000002960 penicillins Chemical class 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 229960001589 posaconazole Drugs 0.000 claims description 4
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims description 4
- 229960001621 povidone-iodine Drugs 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 150000007660 quinolones Chemical class 0.000 claims description 4
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 claims description 4
- 229940081192 rifamycins Drugs 0.000 claims description 4
- 229940100890 silver compound Drugs 0.000 claims description 4
- 150000003379 silver compounds Chemical class 0.000 claims description 4
- 229940041030 streptogramins Drugs 0.000 claims description 4
- 229940124530 sulfonamide Drugs 0.000 claims description 4
- 150000003456 sulfonamides Chemical class 0.000 claims description 4
- 235000019364 tetracycline Nutrition 0.000 claims description 4
- 150000003522 tetracyclines Chemical class 0.000 claims description 4
- 229940040944 tetracyclines Drugs 0.000 claims description 4
- 229960005053 tinidazole Drugs 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 229960004740 voriconazole Drugs 0.000 claims description 4
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 4
- 150000003952 β-lactams Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 3
- 229920006254 polymer film Polymers 0.000 claims 2
- 238000000151 deposition Methods 0.000 claims 1
- 229920005570 flexible polymer Polymers 0.000 claims 1
- 230000036074 healthy skin Effects 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 239000002019 doping agent Substances 0.000 abstract description 5
- 230000000843 anti-fungal effect Effects 0.000 abstract description 4
- 230000000840 anti-viral effect Effects 0.000 abstract description 4
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- 239000010410 layer Substances 0.000 description 6
- 208000031650 Surgical Wound Infection Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010894 electron beam technology Methods 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000031074 Reinjury Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/023—Adhesive bandages or dressings wound covering film layers without a fluid retention layer
- A61F13/0233—Adhesive bandages or dressings wound covering film layers without a fluid retention layer characterised by the oclusive layer skin contacting layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
- A61F13/0253—Adhesive bandages or dressings characterised by the skin-adhering layer characterized by the adhesive material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
Definitions
- the present invention relates to drapes for the protection of living tissues. More particularly, it relates to flexible incise surgical drapes which are useful in the protection of human and animal skin from attack by harmful agents such as microorganisms, and from damage due to physical stresses imposed by detachment of the drape from the skin.
- the drape is comprised of a structural layer and a specially adapted adhesive hydrogel layer, the hydrogel layer optionally containing dopants such as antibiotics, antivirals, antifungals, salts, colorants and medications.
- Surgical drapes are commonly used by medical personnel to create and maintain a sterile field through which the patient may be accessed for a surgical procedure.
- Surgical drapes can help reduce the risk of surgical site infections by immobilizing microorganisms on the skin and by providing continuous antimicrobial activity.
- Surgical drapes may also provide a fluid-resistant barrier. Many drapes feature an absorbent, protective barrier of material throughout the drape that inhibits strikethrough and provides resistance to microbial penetration.
- Surgical site infections are both damaging to patient recovery and expensive to treat. On average, a surgical site infection adds 9.7 more post operative hospital days and costs $20,842 in extra hospital charges (de Lissovoy G, Fraeman K, Hutchins V, Murphy D, Song D, Vaughn BB. Surgical Site Infection: Incidence and Impact on Hospital Utilization and Treatment Costs. Am J Infect Control 2009; 37:387-97.)
- hydrogels as wound dressings, specifically because these dressings exhibit no adhesion to the wound. That is the reason that they are used to cover bums, as the lack of adhesion allows the healing tissue to move freely and reduces scarring. When dressings are changed, the lack of adhesion prevents reinjury to the underlying tissue.
- Some patients needing surgery have skin that is more fragile than usual and is prone to damage from applied forces. Such patients may suffer from skin ailments ranging from autoimmune diseases of the skin to damage from infections by vims, bacteria, and fungus, to advanced age that results in frailty of the skin. In such patients, removal of a surgical drape that is affixed to the skin by an adhesive often results in erythema, skin stripping, and adhesive residue damage to the skin requiring follow-up intervention to prevent and treat infection and to promote healing.
- the hydrogel of the present invention has sufficient adhesion to retain the surgical drape in position during a surgical procedure, and yet exhibits little or no peel force at high peel angles so that removing the drape does not inflict injury on the skin to which it is adhered.
- FIG. l is a section view of a surgical drape according to the present invention.
- the present invention is a surgical drape comprised of a flexible film having disposed on one surface a hydrogel adhesive formulated and processed to provide good adhesion to skin, combined with very low peeling force required for removal of the drape.
- the hydrogel may contain one or more dopants providing antibiotic, antiviral and/or antifungal properties to the hydrogel.
- the drape is removed from the skin by peeling at a high angle, preferably greater than 160° to reduce the force transmitted to the underlying skin.
- an incise surgical drape comprising:
- a flexible film having a top surface and a bottom surface
- a hydrogel adhesive layer disposed on the bottom surface of the film; a.
- the hydrogel comprising a mixture of from 10% to 30% polyvinylpyrrolidone (PVP, e.g, K90) and from 5% to 40% Polyethylene glycol (e.g., PEG 300,
- the hydrogel may contain one or more dopants (additives) selected to provide desired properties such as antibacterial, antiviral, and antifungal, coloring, or other medication.
- dopants additives selected to provide desired properties such as antibacterial, antiviral, and antifungal, coloring, or other medication.
- Drape 10 comprises a flexible film 11 having a top surface 11a and a bottom surface 1 lb. Disposed on bottom surface 1 lb is a hydrogel layer 12.
- flexible film 11 is comprised of polyethylene, and may be any appropriate thickness as required for structural stability and flexibility, as well as suitability for incision during a surgical procedure.
- other polymeric films known in the art may be employed.
- other films or fabrics having sufficient dimensional strength may be employed, such as woven or non-woven fabrics comprising natural fibers, synthetic fibers, or a mixture thereof.
- a uniform degassed slurry comprising a mixture of from 10% to 30% polyvinylpyrrolidone (PVP, K90) and from 5% to 40% Polyethylene glycol (PEG 300), by weight, with the remainder being water, and small amounts of an organic acid (e.g., citric acid) to adjust pH to within a range of 4 to 9, and a medically acceptable preservative (e.g., 0.1% benzalkonium chloride solution or parabens) is prepared.
- the slurry is uniformly deposited or extruded onto film 11, and the slurry is then exposed to electron beam radiation to initiate crosslinking of the PVP and PEG, thereby forming hydrogel layer 12.
- Electron beam energy used may range from 1 megarad to 12 megarads. Varying the ratio of PVP to PEG, the concentration of the mixture in the slurry, and the amount of electron radiation exposure permits hydrogels having varying degrees of adhesion to skin to be produced.
- the peel force required to remove the surgical drape from clean stainless steel is at or near 0 grams using a 180° peel angle, and less than 65 grams using a 90° peel angle.
- Alternative embodiments may exhibit peel force up to 10 grams using a 180° peel angle. In practice, fragile skin is left undamaged by removal of the surgical drape of the present invention, even after an extended period of adhesion.
- An alternative embodiment may substitute PEG 400 for some or all of the PEG 300.
- Another embodiment may add a dopant to the slurry to provide antibacterial, antifungal, and/or antiviral activity, selected from the following:
- Lipopeptides Fluoroquinolone; Lipoglycopeptides; Cephalosporin; Macrocyclics; Beta- lactams; Penicillins; Cephalosporins; Oxacephems; Carbacephems; Monobactams; Carbapenems; Macrolides; Lincosamides; Streptogramins; Aminoglycosides; Quinolones; Sulfonamides; Tetracyclines; Chloramphenicol; Metronidazole; Tinidazole; Nitrofurantoin; Glycopeptides; Lipoglycopeptides; Oxazolidinones; Rifamycins; Polypeptides; Tuberactinomycins; Topical antibiotics (including silver compounds, chitosan, antimicrobial peptides); Betadyne; Chlorhexadine; Povidone-iodine; Iodine; Hydrogen Peroxide; Nystatin;
- Example 1 (Prior Art): 3MTM IobanTM 2 Antimicrobial Incise Drape:
- Example 3 20% PVP / 20% PEG approx. 6 mils thick
- Example 4 25% PVP / 15% PEG approx. 6 mils thick
- Example 5 20% PVP / 17.5% PEG approx. 6 mils thick
- Example 7 25% PVP / 25% PEG approx. 7 mils thick
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
La présente invention concerne un champ opératoire d'incision composé d'un film souple ayant disposé sur une surface un adhésif d'hydrogel formulé et traité pour fournir une bonne adhérence à la peau, associé à une très faible force de décollement requise pour le retrait du champ. Éventuellement, l'hydrogel peut contenir un ou plusieurs agents dopants fournissant des propriétés antibiotiques, antivirales et/ou antifongiques à l'hydrogel. Lors de l'utilisation, le champ est retiré de la peau par décollement sous un angle élevé, préférablement supérieur à 160 ° pour réduire la force transmise à la peau sous-jacente.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021445517A AU2021445517A1 (en) | 2021-05-08 | 2021-08-20 | Surgical drape for use on fragile skin and method of use thereof |
| KR1020237042225A KR20240017821A (ko) | 2021-05-08 | 2021-08-20 | 연약한 피부에 사용하기 위한 수술용 드레이프 및 그 사용 방법 |
| EP21942116.1A EP4333913A1 (fr) | 2021-05-08 | 2021-08-20 | Champ opératoire pour l'utilisation sur une peau fragile et son procédé d'utilisation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163186079P | 2021-05-08 | 2021-05-08 | |
| US63/186,079 | 2021-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022240431A1 true WO2022240431A1 (fr) | 2022-11-17 |
Family
ID=84027772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2021/046940 WO2022240431A1 (fr) | 2021-05-08 | 2021-08-20 | Champ opératoire pour l'utilisation sur une peau fragile et son procédé d'utilisation |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4333913A1 (fr) |
| KR (1) | KR20240017821A (fr) |
| AU (1) | AU2021445517A1 (fr) |
| WO (1) | WO2022240431A1 (fr) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4750482A (en) * | 1982-02-25 | 1988-06-14 | Pfizer Inc. | Hydrophilic, elastomeric, pressure-sensitive adhesive |
| US5306504A (en) * | 1992-12-09 | 1994-04-26 | Paper Manufactures Company | Skin adhesive hydrogel, its preparation and uses |
| US5419913A (en) * | 1992-03-05 | 1995-05-30 | Podell; Howard I. | Adhesive bandages, wound dressings, sutures, drapes, orthodontic rubber bands, toothbrushes, and the like |
| US5645855A (en) * | 1996-03-13 | 1997-07-08 | Ridge Scientific Enterprises, Inc. | Adhesive compositions including polyvinylpyrrolidone acrylic acid polymers, and polyamines |
| US20080193706A1 (en) * | 2004-05-12 | 2008-08-14 | Shunsuke Takaki | Iodine-Containing Hot Melt Pressure Sensitive Adhesive Capable Of Being Melted And Coated At A Temperature Not Higher Than 100c, And A Medical Adhesive Sheet Product With Such A Pressure Sensitive Adhesive |
-
2021
- 2021-08-20 WO PCT/US2021/046940 patent/WO2022240431A1/fr active Application Filing
- 2021-08-20 KR KR1020237042225A patent/KR20240017821A/ko active Search and Examination
- 2021-08-20 EP EP21942116.1A patent/EP4333913A1/fr active Pending
- 2021-08-20 AU AU2021445517A patent/AU2021445517A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4750482A (en) * | 1982-02-25 | 1988-06-14 | Pfizer Inc. | Hydrophilic, elastomeric, pressure-sensitive adhesive |
| US5419913A (en) * | 1992-03-05 | 1995-05-30 | Podell; Howard I. | Adhesive bandages, wound dressings, sutures, drapes, orthodontic rubber bands, toothbrushes, and the like |
| US5306504A (en) * | 1992-12-09 | 1994-04-26 | Paper Manufactures Company | Skin adhesive hydrogel, its preparation and uses |
| US5645855A (en) * | 1996-03-13 | 1997-07-08 | Ridge Scientific Enterprises, Inc. | Adhesive compositions including polyvinylpyrrolidone acrylic acid polymers, and polyamines |
| US20080193706A1 (en) * | 2004-05-12 | 2008-08-14 | Shunsuke Takaki | Iodine-Containing Hot Melt Pressure Sensitive Adhesive Capable Of Being Melted And Coated At A Temperature Not Higher Than 100c, And A Medical Adhesive Sheet Product With Such A Pressure Sensitive Adhesive |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4333913A1 (fr) | 2024-03-13 |
| KR20240017821A (ko) | 2024-02-08 |
| AU2021445517A1 (en) | 2023-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Narkhede et al. | Postoperative mesh infection—still a concern in laparoscopic era | |
| US20190000436A1 (en) | Methods and products for reducing tissue trauma using water-absorbing stress-distributing materials | |
| JP5393030B2 (ja) | 医療機器及び医療機器を製造する方法 | |
| US10485892B2 (en) | Method for local reduction of microbial skin flora | |
| ES2815660T3 (es) | Procedimiento de reducción local de la flora microbiana cutánea | |
| Ahmed et al. | Calcium alginate-based antimicrobial film dressings for potential healing of infected foot ulcers | |
| US8609128B2 (en) | Cyanoacrylate-based liquid microbial sealant drape | |
| US20070009580A1 (en) | Non-adhesive hydrogels | |
| KR20060018878A (ko) | 접착제 조성물, 이를 포함하는 물품 및 제조 방법 | |
| JP6803382B2 (ja) | 外科的用途のための抗菌性組成物 | |
| US8951552B2 (en) | In situ film-forming bioactive solutions of absorbable multiblock copolymers | |
| WO2014130567A1 (fr) | Polymères d'hydrogel antimicrobiens | |
| Shiels et al. | Chlorhexidine-releasing implant coating on intramedullary nail reduces infection in a rat model | |
| CN107921283A (zh) | 包括阿来西定的伤口护理产品 | |
| US20070036846A1 (en) | Wound dressing and method of manufacture thereof | |
| WO2022240431A1 (fr) | Champ opératoire pour l'utilisation sur une peau fragile et son procédé d'utilisation | |
| KR102096257B1 (ko) | 폴리비닐피롤리돈 및 유니티올을 포함하는 방부제 조성물 및 조성물의 용도 | |
| EP2381974B1 (fr) | Procédé de formation et composition membranaire résultante pour préservation de site chirurgical | |
| US8828425B2 (en) | In situ-formed bioactive tissue adherent films of absorbable crystallizable polymers | |
| Shi et al. | The value of continuous closed negative pressure drainage combined with antibacterial biofilm dressing in postoperative wound healing for severe pancreatitis | |
| Cases | A comparative study of chlorhexidine-alcohol versus povidone-iodine for surgical site antisepsis in clean & clean contaminated cases | |
| Thomas et al. | Improvements in medicated tulle dressings | |
| Singh et al. | AURAL HAEMATOMA IN BEETAL BUCK (MALE GOAT): A CASE REPORT. | |
| RU2790779C1 (ru) | Способ лечения остаточных длительно существующих ожоговых ран | |
| Babina et al. | Effectiveness of Perioperative Local Use of Anesthetics and Antiseptics in Patients with Purulent-necrotic Lesions of Lower Extremities in Diabetes Mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21942116 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2021445517 Country of ref document: AU Ref document number: AU2021445517 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2021942116 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2021445517 Country of ref document: AU Date of ref document: 20210820 Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2021942116 Country of ref document: EP Effective date: 20231208 |